IT1190282B - Composizioni di fenitoina per somministrazione parenterale e procedimento di preparazione - Google Patents

Composizioni di fenitoina per somministrazione parenterale e procedimento di preparazione

Info

Publication number
IT1190282B
IT1190282B IT47936/86A IT4793686A IT1190282B IT 1190282 B IT1190282 B IT 1190282B IT 47936/86 A IT47936/86 A IT 47936/86A IT 4793686 A IT4793686 A IT 4793686A IT 1190282 B IT1190282 B IT 1190282B
Authority
IT
Italy
Prior art keywords
fenitoin
compositions
parenteral administration
preparation procedure
procedure
Prior art date
Application number
IT47936/86A
Other languages
English (en)
Other versions
IT8647936A1 (it
IT8647936A0 (it
Inventor
Mahdi B Fawzi
Anne K Taylor
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of IT8647936A0 publication Critical patent/IT8647936A0/it
Publication of IT8647936A1 publication Critical patent/IT8647936A1/it
Application granted granted Critical
Publication of IT1190282B publication Critical patent/IT1190282B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IT47936/86A 1985-05-20 1986-04-24 Composizioni di fenitoina per somministrazione parenterale e procedimento di preparazione IT1190282B (it)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/735,932 US4642316A (en) 1985-05-20 1985-05-20 Parenteral phenytoin preparations

Publications (3)

Publication Number Publication Date
IT8647936A0 IT8647936A0 (it) 1986-04-24
IT8647936A1 IT8647936A1 (it) 1987-10-24
IT1190282B true IT1190282B (it) 1988-02-16

Family

ID=24957819

Family Applications (1)

Application Number Title Priority Date Filing Date
IT47936/86A IT1190282B (it) 1985-05-20 1986-04-24 Composizioni di fenitoina per somministrazione parenterale e procedimento di preparazione

Country Status (18)

Country Link
US (1) US4642316A (it)
JP (1) JPS61268618A (it)
AU (1) AU595790B2 (it)
BE (1) BE904476A (it)
CA (1) CA1268119A (it)
CH (1) CH668594A5 (it)
DE (1) DE3610330A1 (it)
DK (1) DK100786A (it)
ES (1) ES8707195A1 (it)
FR (1) FR2581871B1 (it)
GB (1) GB2175203B (it)
IT (1) IT1190282B (it)
LU (1) LU86383A1 (it)
NL (1) NL8600899A (it)
NZ (1) NZ215783A (it)
PH (1) PH22922A (it)
SE (1) SE8600998L (it)
ZA (1) ZA862094B (it)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3828156A1 (de) * 1988-08-19 1990-02-22 Astrapin Pharmazeutische Praep Stabile waessrige loesung von fluorouracil
WO1999004798A1 (en) * 1997-07-22 1999-02-04 Warner-Lambert Company Lyophilized fosphenytoin sodium for parenteral use
AU1917899A (en) 1998-03-20 1999-10-18 Warner-Lambert Company Crystalline sodium phenytoin monohydrate
US6274168B1 (en) 1999-02-23 2001-08-14 Mylan Pharmaceuticals Inc. Phenytoin sodium pharmaceutical compositions
AU2003288588A1 (en) * 2002-12-16 2004-07-09 Ranbaxy Laboratories Limited An extended release pharmaceutical composition of phenytoin sodium
EP2502649A1 (en) 2005-02-03 2012-09-26 TopoTarget UK Limited Combination therapy using HDAC inhibitors and erlotinib for treating cancer
DE102005019393A1 (de) * 2005-04-25 2006-10-26 Basell Polyolefine Gmbh Polyethylenformmassen für Spritzgussanwendungen
ATE542527T1 (de) 2005-05-13 2012-02-15 Topotarget Uk Ltd Pharmazeutische formulierungen von hdac-hemmern
AU2012213940B2 (en) * 2005-05-13 2015-03-26 Topotarget Uk Limited Pharmaceutical formulations of HDAC inhibitors
CA2627923C (en) * 2005-11-10 2016-01-12 Topotarget Uk Limited Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer
US8377979B2 (en) * 2005-12-05 2013-02-19 Taro Pharmaceuticals North America, Inc. Pharmaceutical formulation containing phenytoin sodium and magnesium stearate
US8642809B2 (en) * 2007-09-25 2014-02-04 Topotarget Uk Ltd. Methods of synthesis of certain hydroxamic acid compounds
AU2009220942B2 (en) * 2008-03-07 2015-05-28 Onxeo Dk, Branch Of Onxeo S.A., France Methods of treatment employing prolonged continuous infusion of Belinostat
GB0900555D0 (en) * 2009-01-14 2009-02-11 Topotarget As New methods
SG10201505101VA (en) * 2009-05-19 2015-07-30 Neuroderm Ltd Compositions For Continuous Administration Of Dopa Decarboxylase Inhibitors
SI2640358T1 (en) 2010-11-15 2018-05-31 Neuroderm Ltd. Continuous administration of L-dopa, dopamine decarboxylase inhibitors, catechol-O-methyl transferase inhibitors, and compositions thereof
WO2012082995A1 (en) 2010-12-15 2012-06-21 Nektar Therapeutics Oligomer-containing hydantoin compounds
AU2013273138B2 (en) 2012-06-05 2017-06-15 Neuroderm Ltd Compositions comprising apomorphine and organic acids and uses thereof
WO2015136538A1 (en) 2014-03-13 2015-09-17 Neuroderm Ltd Dopa decarboxylase inhibitor compositions
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
WO2023205615A1 (en) * 2022-04-18 2023-10-26 ISHA Therapeutics LLC Orally dissolving antimicrobial film compositions & methods of their use
US12109303B2 (en) 2022-04-18 2024-10-08 ISHA Therapeutics LLC Orally dissolving antimicrobial film compositions and methods of their use
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3749779A (en) * 1970-08-27 1973-07-31 American Home Prod Stable solutions of sodium diphenylhydantoin
JPS5221575B2 (it) * 1972-03-18 1977-06-11
US4260769A (en) * 1977-04-22 1981-04-07 Interx Research Corporation 5,5-Diphenylhydantoins
US4163058A (en) * 1977-04-22 1979-07-31 Interx Research Corporation Derivatives of 5,5-diphenylhydantoin exhibiting enhanced solubility and the therapeutic use thereof

Also Published As

Publication number Publication date
ES555143A0 (es) 1987-07-16
PH22922A (en) 1989-01-24
CA1268119A (en) 1990-04-24
IT8647936A1 (it) 1987-10-24
LU86383A1 (fr) 1986-09-02
CH668594A5 (fr) 1989-01-13
SE8600998D0 (sv) 1986-03-05
NL8600899A (nl) 1986-12-16
DK100786A (da) 1986-11-21
GB8607383D0 (en) 1986-04-30
AU595790B2 (en) 1990-04-12
NZ215783A (en) 1989-01-27
FR2581871A1 (fr) 1986-11-21
GB2175203A (en) 1986-11-26
ES8707195A1 (es) 1987-07-16
ZA862094B (en) 1986-11-26
JPS61268618A (ja) 1986-11-28
DE3610330A1 (de) 1986-11-20
FR2581871B1 (fr) 1990-05-11
US4642316A (en) 1987-02-10
IT8647936A0 (it) 1986-04-24
GB2175203B (en) 1988-09-14
DK100786D0 (da) 1986-03-05
BE904476A (fr) 1986-09-24
SE8600998L (sv) 1986-11-21
AU5441286A (en) 1986-11-27

Similar Documents

Publication Publication Date Title
IT1190282B (it) Composizioni di fenitoina per somministrazione parenterale e procedimento di preparazione
IL80411A (en) Preparation of dibenzopyranol derivatives and pharmaceutical compositions containing them
IL80370A (en) Preparation of sucralose
NZ216793A (en) Phenethanolaminotetraline derivatives and pharmaceutical compositions
GB2181346B (en) Pharmaceutical compositions and medical uses of dioxopiperidine derivatives
NZ217126A (en) Tert-butylphenol derivatives and pharmaceutical compositions
NZ215871A (en) Fluorinated phenylalkyl-triazole derivatives and pharmaceutical compositions
NZ217342A (en) 4-amino-n-(alkyl n -p-benzamide derivatives and pharmaceutical compositions
NZ217078A (en) N-piperidyl-benzamide derivatives and pharmaceutical compositions
IL78959A0 (en) Preparation of gamma-globulins suitable for intravenous administration
IT1200400B (it) Procedimento per la preparazione di 2-alchil ciclopent-2-enoni
NZ216720A (en) Diazinylpiperidine derivatives and pharmaceutical compositions
AU5811986A (en) Epoxy-phosphate ceramic compositions and methods of preparation
IT1200594B (it) Procedimento per la preparazione di alfa-omega-aloperfluorocarburi
IL80307A0 (en) Preparation of phenylpropanone derivatives
NZ214815A (en) 12-aminopyridazinopyrroloisoquinoline derivatives and pharmaceutical compositions
IT1191806B (it) Procedimento per la preparazione di 2-bromo-alfa-ergocriptina
IT1190358B (it) Procedimento per la preparazione di l-carnitina
IL79438A0 (en) Preparation of 2-cyanoaminopyrimidine derivatives
IT8548297A0 (it) Procedimento per la preparazione di r(-)-norcarnitina terz-butil estere
IT1214685B (it) Preparazioni di coloranti stabili
IT1185513B (it) Procedimento per l'ottenimento di preparati farmaceutici con effetto ritardato
IT1231426B (it) Preparazione di polifluoroenolati
IT1189462B (it) Procedimento per la preparazione di derivati della eburnamenina e composizioni farmaceutiche che li contengono
IT8519620A0 (it) Procedimento per la preparazione di amidinouree e composizioni farmaceutiche che le contengono